# A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases

> **NCT07049081** · PHASE1 · RECRUITING · sponsor: **Nanjing Legend Biotech Co.** · enrollment: 42 (estimated)

## Conditions studied

- Relapsed/Refractory Autoimmune Diseases

## Interventions

- **BIOLOGICAL:** LUCAR-G79 T cells

## Key facts

- **NCT ID:** NCT07049081
- **Lead sponsor:** Nanjing Legend Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-17
- **Primary completion:** 2028-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07049081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07049081, "A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07049081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*